PsychedelicNewsBreaks

ThursdaySep 08, 2022 11:35 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO to Present at H.C. Wainwright Annual Global Investment Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that CEO Matt Stang will be participating in the 24th annual H.C. Wainwright Annual Global Investment Conference. The three-day event is scheduled for Sept. 12–14, 2022. During his presentation, Stang will provide a summary of the company’s focus on growing its clinic footprint and accepting a wider selection of insurance options; the presentation will also include Delic’s strategic outlook for the remainder of the year. In addition, Stang will be available for one-on-one meetings throughout the conference. Stang’s presentation will…

Continue Reading

WednesdaySep 07, 2022 11:08 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Makes Top-100 Innovation List, Company Postpones Meet Delic Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Matt Stang was included in World Biz magazine’s Top-100 CEOs in Innovation for 2022. The announcement noted that Stang was recognized as a champion of creativity who is dedicated to making a positive environmental and social impact. Stand cofounded Delic Corp., which has grown into a leader in new medicines and treatments for a modern world. Stang led the company’s acquisition of the Ketamine Wellness Centers, and under his guidance, the company reported more than $1.5 million in total revenue in 2021 while more than quadrupling its net assets. This month, Stang…

Continue Reading

TuesdaySep 06, 2022 12:32 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Secures FDA and Health Canada Approval for Phase 2 Trial of FSD201

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced its receipt of a “Study May Proceed” letter for the Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its phase 2 clinical trial of FSD201. The trial will study the safety and efficacy of FSD201 in patients with chronic widespread musculoskeletal nociplastic pain associated with idiopathic mast cell activation syndrome. “We are delighted to…

Continue Reading

WednesdayAug 31, 2022 12:31 pm

PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Marks Final Development Milestone

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved the milestone identified as Y2, Q4(ii) as contemplated by the terms of a contribution agreement dated Dec. 4, 2020, among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “acquiror”), a wholly controlled subsidiary of Cybin, and all of the previous shareholders of Adelia. “This final development milestone marks the completion of a detailed series of goals set between Cybin and Adelia almost two years ago. Our combined teams have executed…

Continue Reading

TuesdayAug 30, 2022 10:47 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical development. The company is conducting a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD in which participants will receive two administrations (placebo/active and active/active) with a response assessed at week 3 after first dose and at week 6 after second dose. “To…

Continue Reading

ThursdayAug 25, 2022 1:26 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research

Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder and chronic back pain,’” a recent article reads. According to Silo Pharma CEO Eric Weisblum, the company is encouraged by the progress and looks forward to the next cohort of patients receiving therapeutic treatment and sharing the analysis of…

Continue Reading

ThursdayAug 25, 2022 11:11 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming H.C. Wainwright Global Investment Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the H.C. Wainwright 24th annual Global Investment Conference; the elite event is slated for Sept. 12–14, 2022. CYBN CEO Doug Drysdale will present in a virtual fireside chat during the conference. The company announced that his presentation will be available starting Sept. 12 at 7 a.m. ET. An archived copy of the presentation will also be available on Cybin’s website following the event. To view the presentation, visit https://ibn.fm/OUzui   To view the full press release, visit https://ibn.fm/Ra3Tn About Cybin Inc. Cybin…

Continue Reading

TuesdayAug 16, 2022 1:13 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Key Management Positions

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, have announced advanced appointments for two key executives. According to the company, Delic Holdings cofounder and CEO Matt Stang has been named executive chair while COO Kevin Nicholson has been named CEO and will also join the company’s board of directors; Nicholson will continue to serve in his current role as CEO of Ketamine Wellness Centers (“KWC”). Before founding Delic, Stang owned and operated “High Times,”a leading source of cannabis news. As Delic CEO, Stang led the company in its acquisition of…

Continue Reading

TuesdayAug 16, 2022 11:45 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM)”, today announced voting results for each of the matters presented at the company’s annual shareholders’ meeting. There were 71 shareholders represented in person or by proxy, holding 47,019,721 common shares, representing 28.3% of Cybin’s total issued and outstanding common shares as at the record date for the meeting held on Aug. 15, 2022. The announcement details voting results for each matter presented, including the appointment of Zeifmans LLP as auditor and election of directors. Each of the nominees listed in Cybin’s July 13 management information…

Continue Reading

FridayAug 12, 2022 2:58 pm

PsychedelicNewsBreaks – Silo Pharma Inc.’s (SILO) Ketamine Study Generates ‘Extremely Promising’ Data

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, recently completed an animal study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics. “Results from the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre- and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the pre-dose time point. ‘These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its…

Continue Reading